News

In this new position, Mr Evashenk will assist in defining developmental strategy, guiding clinical protocol design and study conduct, and managing risk assessment. He will report to Pamela

For the year 2008, Noven reported a net income of $21.4 million, or $0.87 per diluted share, compared to a net loss of $45.4 million, or $1.84 per

Sanofi-aventis has signed an agreement with the Mexican authorities to build a E100m facility to manufacture influenza vaccine in Mexico. The agreement was signed by Birmex’ (Laboratorio de

Yet, people on both sides of the stem cell debate say Obama’s announcement could lead to a reconsideration of the ban on Capitol Hill, an idea so controversial

Hana Biosciences has announced new positive preliminary efficacy results from a planned interim analysis of the ongoing pivotal rALLy clinical trial evaluating Marqibo for the treatment of adult

Abraxis BioScience, a fully integrated biotechnology company, has reported a net loss of $181.9m, or $4.54 per share, for the fourth quarter of 2008, compared with a net

SciClone Pharmaceuticals, a biopharmaceutical company, has reported a net loss of $3.14m, or $0.07 per share, for the fourth quarter of 2008, compared with a net loss of

Halo Pharmaceutical, a provider of contract manufacturing, formulation development and laboratory testing services, has announced that it is establishing a new Canadian subsidiary to be called Halo Pharmaceutical

Novexel, a specialty pharmaceutical company, has announced that its most advanced injectable antibacterial, which combines the company’s broad spectrum beta lactamase inhibitor, NXL104, with the well established cephalosporin